Effects of administration of adipose-derived stromal vascular fraction and platelet-rich plasma to dogs with osteoarthritis of the hip joints

David A. Upchurch Department of Clinical Science, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506

Search for other papers by David A. Upchurch in
Current site
Google Scholar
PubMed
Close
 DVM
,
Walter C. Renberg Department of Clinical Science, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506

Search for other papers by Walter C. Renberg in
Current site
Google Scholar
PubMed
Close
 DVM, MS
,
James K. Roush Department of Clinical Science, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506

Search for other papers by James K. Roush in
Current site
Google Scholar
PubMed
Close
 DVM, MS
,
George A. Milliken Milliken Associates Inc, 1401 Deep Creek Ln, Manhattan, KS 66502.

Search for other papers by George A. Milliken in
Current site
Google Scholar
PubMed
Close
 PhD
, and
Mark L. Weiss Department of Anatomy and Physiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506

Search for other papers by Mark L. Weiss in
Current site
Google Scholar
PubMed
Close
 PhD

Abstract

OBJECTIVE To evaluate effects of simultaneous intra-articular and IV injection of autologous adipose-derived stromal vascular fraction (SVF) and platelet-rich plasma (PRP) to dogs with osteoarthritis of the hip joints.

ANIMALS 22 client-owned dogs (12 placebo-treated [control] dogs and 10 treated dogs).

PROCEDURES Dogs with osteoarthritis of the hip joints that caused signs of lameness or discomfort were characterized on the basis of results of orthopedic examination, goniometry, lameness score, the Canine Brief Pain Inventory (CBPI), a visual analogue scale, and results obtained by use of a pressure-sensing walkway at week 0 (baseline). Dogs received a simultaneous intraarticular and IV injection of SVF and PRP or a placebo. Dogs were examined again 4, 8, 12, and 24 weeks after injection.

RESULTS CBPI scores were significantly lower for the treatment group at week 24, compared with scores for the control group. Mean visual analogue scale score for the treatment group was significantly higher at week 0 than at weeks 4, 8, or 24. Dogs with baseline peak vertical force (PVF) in the lowest 25th percentile were compared, and the treatment group had a significantly higher PVF than did the control group. After the SVF-PRP injection, fewer dogs in the treated group than in the control group had lameness confirmed during examination.

CONCLUSIONS AND CLINICAL RELEVANCE For dogs with osteoarthritis of the hip joints treated with SVF and PRP, improvements in CBPI and PVF were evident at some time points, compared with results for the control group.

Abstract

OBJECTIVE To evaluate effects of simultaneous intra-articular and IV injection of autologous adipose-derived stromal vascular fraction (SVF) and platelet-rich plasma (PRP) to dogs with osteoarthritis of the hip joints.

ANIMALS 22 client-owned dogs (12 placebo-treated [control] dogs and 10 treated dogs).

PROCEDURES Dogs with osteoarthritis of the hip joints that caused signs of lameness or discomfort were characterized on the basis of results of orthopedic examination, goniometry, lameness score, the Canine Brief Pain Inventory (CBPI), a visual analogue scale, and results obtained by use of a pressure-sensing walkway at week 0 (baseline). Dogs received a simultaneous intraarticular and IV injection of SVF and PRP or a placebo. Dogs were examined again 4, 8, 12, and 24 weeks after injection.

RESULTS CBPI scores were significantly lower for the treatment group at week 24, compared with scores for the control group. Mean visual analogue scale score for the treatment group was significantly higher at week 0 than at weeks 4, 8, or 24. Dogs with baseline peak vertical force (PVF) in the lowest 25th percentile were compared, and the treatment group had a significantly higher PVF than did the control group. After the SVF-PRP injection, fewer dogs in the treated group than in the control group had lameness confirmed during examination.

CONCLUSIONS AND CLINICAL RELEVANCE For dogs with osteoarthritis of the hip joints treated with SVF and PRP, improvements in CBPI and PVF were evident at some time points, compared with results for the control group.

Contributor Notes

Dr. Upchurch's present address is Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, MI 48824.

Address correspondence to Dr. Upchurch (upchuda@gmail.com).
  • 1. Johnson JA, Austin C, Breur GJ. Incidence of canine appendicular musculoskeletal disorders in 16 veterinary teaching hospitals from 1980 through 1989. Vet Comp Orthop Traumatol 1994; 7: 5–18.

    • Search Google Scholar
    • Export Citation
  • 2. Smith GK, Karbe GT, Agnello KA, et al. Pathogenesis, diagnosis, and control of canine hip dysplasia. In: Tobias K, Johnston SA, eds. Veterinary surgery: small animal. Vol 1. St Louis: WB Saunders Co, 2012;824–848.

    • Search Google Scholar
    • Export Citation
  • 3. Corley EA. Hip dysplasia: a report from the Orthopedic Foundation for Animals. Semin Vet Med Surg (Small Anim) 1987; 2: 141–151.

    • Search Google Scholar
    • Export Citation
  • 4. Coopman F, Verhoeven G, Saunders J, et al. Prevalence of hip dysplasia, elbow dysplasia and humeral head osteochondrosis in dog breeds in Belgium. Vet Rec 2008; 163: 654–658.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5. Renberg WC. Pathophysiology and management of arthritis. Vet Clin North Am Small Anim Pract 2005; 35: 1073–1091.

  • 6. Jack GS, Almeida FG, Zhang R, et al. Processed lipoaspirate cells for tissue engineering of the lower urinary tract: implications for the treatment of stress urinary incontinence and bladder reconstruction. J Urol 2005; 174: 2041–2045.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7. Gimble JM, Katz AJ, Bunnell BA. Adipose-derived stem cells for regenerative medicine. Circ Res 2007; 100: 1249–1260.

  • 8. Chen FH, Tuan RS. Mesenchymal stem cells in arthritic diseases. Arthritis Res Ther 2008; 10: 223–234.

  • 9. Fang B, Song Y, Zhao RC, et al. Using human adipose tissue-derived mesenchymal stem cells as salvage therapy for hepatic graft-vs-host disease resembling acute hepatitis. Transplant Proc 2007; 39: 1710–1713.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10. Wood JA, Chung D, Park SA, et al. Periocular and intra-articular injection of canine adipose-derived mesenchymal stem cells—an in vivo imaging and migration study. J Ocul Pharmacol Ther 2012; 28: 307–317.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11. Djouad F, Charbonnier LM, Bouffi C, et al. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells 2007; 25: 2025–2032.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12. Németh K, Leelahavanichkul A, Yuen PS, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E2-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 2009; 15: 42–49.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13. Sullivan C, Barry F, Ritter T, et al. Allogeneic murine mesenchymal stem cells: migration to inflamed joints in vivo and amelioration of collagen induced arthritis when transduced to express CTLA4Ig. Stem Cells Dev 2013; 22: 3203–3213.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 14. Murphy JM, Fink DJ, Hunziker EB, et al. Stem cell therapy in a caprine model of osteoarthritis. Arthritis Rheum 2003; 48: 3464–3474.

  • 15. Horie M, Sekiya I, Muneta T, et al. Intra-articular injected synovial stem cells differentiate into meniscal cells directly and promote meniscal regeneration without mobilization to distant organs in rat massive meniscal defect. Stem Cells 2009; 27: 878–887.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16. Lee KB, Hui JH, Song IC, et al. Injectable mesenchymal stem cell therapy for large cartilage defects—a porcine model. Stem Cells 2007; 25: 2964–2971.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 17. Augello A, Tasso R, Negrini SM, et al. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum 2007; 56: 1175–1186.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 18. Guercio A, Marco P, Casella S, et al. Production of canine mesenchymal stem cells from adipose tissue and their application in dogs with chronic osteoarthritis of the humeroradial joints. Cell Biol Int 2012; 36: 189–194.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 19. Ferris DJ, Frisbie DD, Kisiday JD, et al. Clinical outcome after intra-articular administration of bone marrow derived mesenchymal stem cells in 33 horses with stifle injury. Vet Surg 2014; 43: 255–265.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 20. Cuervo B, Rubio M, Sopena J, et al. Hip osteoarthritis in dogs: a randomized study using mesenchymal stem cells from adipose tissue and plasma rich in growth factors. Int J Mol Sci 2014; 15: 13437–13460.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 21. Vilar JM, Batista M, Morales M, et al. Assessment of the effect of intraarticular injection of autologous adipose-derived mesenchymal stem cells in osteoarthritic dogs using a double blinded force platform analysis. BMC Vet Res 2014; 10: 143.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 22. Vilar JM, Morales M, Santana A, et al. Controlled, blinded force platform analysis of the effect of intraarticular injection of autologous adipose-derived mesenchymal stem cells associated to PRGF-Endoret in osteoarthritic dogs. BMC Vet Res 2013; 9: 131.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 23. US Department of Health and Human Services FDA Center for Veterinary Medicine. Cell-based products for animal use. Industry guidance #218. Rockville, Md: FDA Center for Veterinary Medicine, 2015;1–14.

    • Search Google Scholar
    • Export Citation
  • 24. Prockop DJ, Brenner M, Fibbe WE, et al. Defining the risks of mesenchymal stromal cell therapy. Cytotherapy 2010; 12: 576–578.

  • 25. Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS ONE 2012; 7: e47559.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 26. Tatsumi K, Ohashi K, Matsubara Y, et al. Tissue factor triggers procoagulation in transplanted mesenchymal stem cells leading to thromboembolism. Biochem Biophys Res Commun 2013; 431: 203–209.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 27. Jung JW, Kwon M, Choi JC, et al. Familial occurrence of pulmonary embolism after intravenous, adipose tissue-derived stem cell therapy. Yonsei Med J 2013; 54: 1293–1296.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 28. Cyranoski D. Stem cells boom in vet clinic. Nature 2013; 496: 148–149.

  • 29. Black LL, Gaynor J, Gehring D, et al. Effect of adipose-derived mesenchymal stem and regenerative cells on lameness in dogs with chronic osteoarthritis of the coxofemoral joints: a randomized, double-blinded, multicenter controlled trial. Vet Ther 2007; 8: 272–284.

    • Search Google Scholar
    • Export Citation
  • 30. Black LL, Gaynor J, Adams C, et al. Effect of intraarticular injection of autologous adipose-derived mesenchymal stem and regenerative cells on clinical signs of chronic osteoarthritis of the elbow joint in dogs. Vet Ther 2008; 9: 192–200.

    • Search Google Scholar
    • Export Citation
  • 31. Marx C, Silveira MD, Selbach I, et al. Acupoint injection of autologous stromal vascular fraction and allogeneic adipose-derived stem cells to treat hip dysplasia in dogs. Stem Cells Int 2014; 2014: 391274.

    • Search Google Scholar
    • Export Citation
  • 32. Frisbie DD, Kisiday JD, Kawcak CE, et al. Evaluation of adipose-derived stromal vascular fraction or bone marrow-derived mesenchymal stem cells for treatment of osteoarthritis. J Orthop Res 2009; 27: 1675–1680.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 33. Qi Y, Feng G, Yan W. Mesenchymal stem cell-based treatment for cartilage defects in osteoarthritis. Mol Biol Rep 2012; 39: 5683–5689.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 34. Bourin P, Bunnell BA, Casteilla L, et al. Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT). Cytotherapy 2013; 15: 641–648.

    • Search Google Scholar
    • Export Citation
  • 35. Webster RA, Blabber SP, Herbert BR, et al. The role of mesenchymal stem cells in veterinary therapeutics—a review. N Z Vet J 2012; 60: 265–272.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 36. Riordan NH, Ichim TE, Min WP, et al. Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis. J Transl Med 2009; 7: 29.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 37. Miranville A, Heeschen C, Sengenes C, et al. Improvement of postnatal neovascularization by human adipose tissue-derived stem cells. Circulation 2004; 110: 349–355.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 38. Zeyda M, Stulnig TM. Adipose tissue macrophages. Immunol Lett 2007; 112: 61–67.

  • 39. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, et al. Macrophage-specific PPARγ; controls alternative activation and improves insulin resistance. Nature 2007; 447: 1116–1120.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 40. Zeyda M, Farmer D, Todoric J, et al. Human adipose tissue macrophages are of an anti-inflammatory phenotype but capable of excessive pro-inflammatory mediator production. Int J Obes (Lond) 2007; 31: 1420–1428.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 41. Fahie MA, Ortolano GA, Guercio V, et al. A randomized controlled trial of the efficacy of autologous platelet therapy for the treatment of osteoarthritis in dogs. J Am Vet Med Assoc 2013;243: 1291–1297.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 42. Van Pham P, Bui KH, Ngo DQ, et al. Activated platelet-rich plasma improves adipose-derived stem cell transplantation efficiency in injured articular cartilage. Stem Cell Res Ther 2013; 4: 91–102.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 43. Brown DC, Boston RC, Coyne JC, et al. Ability of the canine brief pain inventory to detect response to treatment in dogs with osteoarthritis. J Am Vet Med Assoc 2008; 233: 1278–1283.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 44. Brown DC, Bell M, Rhodes L. Power of treatment success definitions when the Canine Brief Pain Inventory is used to evaluate carprofen treatment for the control of pain and inflammation in dogs with osteoarthritis. Am J Vet Res 2013; 74: 1467–1473.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 45. Jaegger G, Marcellin-Little DJ, Levine D. Reliability of goniometry in Labrador Retrievers. Am J Vet Res 2002; 63: 979–986.

  • 46. Hudson JT, Slater MR, Taylor L, et al. Assessing repeatability and validity of a visual analogue scale questionnaire for use in assessing pain and lameness in dogs. Am J Vet Res 2004; 65: 1634–1643.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 47. Franklin SP, Garner BC, Cook JL. Characteristics of canine platelet-rich plasma prepared with five commercially available systems. Am J Vet Res 2015; 76: 822–827.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 48. Smith GK, Paster ER, Powers MY, et al. Lifelong diet restriction and radiographic evidence of osteoarthritis of the hip joint in dogs. J Am Vet Med Assoc 2006; 229: 690–693.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 49. Milliken GA, Johnson DE. One-way analysis of covariance—one covariate in a completely randomized design structure. In: Milliken GA, Johnson DE, eds. Analysis of messy data, volume 3: analysis of covariance. New York: Chapman & Hall/CRC, 2001; 11–39.

    • Search Google Scholar
    • Export Citation
  • 50. Clayton HM. The force plate: established technology, new application. Vet J 2005; 169: 15–16.

  • 51. Cordova ML, Armstrong CW. Reliability of ground reaction forces during a vertical jump: implications for functional strength assessment. J Athl Train 1996; 31: 342–345.

    • Search Google Scholar
    • Export Citation
  • 52. Besancon MF, Conzemius MG, Derrick TR, et al. Comparison of vertical forces in normal Greyhounds between force platform and pressure walkway measurement systems. Vet Comp Orthop Traumatol 2003; 16: 153–157.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 53. Quinn MM, Keuler NS, Lu YAN, et al. Evaluation of agreement between numerical rating scales, visual analogue scoring scales, and force plate gait analysis in dogs. Vet Surg 2007; 36: 360–367.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 54. Horstman CL, Conzemius MG, Evans R, et al. Assessing the efficacy of perioperative oral carprofen after cranial cruciate surgery using noninvasive, objective pressure platform gait analysis. Vet Surg 2004; 33: 286–292.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 55. Oosterlinck M, Bosmans T, Gasthuys F, et al. Accuracy of pressure plate kinetic asymmetry indices and their correlation with visual gait assessment scores in lame and nonlame dogs. Am J Vet Res 2011; 72: 820–825.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 56. Weiss E. Knee osteoarthritis, body mass index and pain: data from the Osteoarthritis Initiative. Rheumatology 2014; 53: 2095–2099.

  • 57. Moreau M, Troncy E, Bichot S, et al. Influence of changes in body weight on peak vertical force in osteoarthritic dogs: a possible bias in study outcome. Vet Surg 2010; 39: 43–47.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 58. Marshall WG, Hazewinkel HA, Mullen D, et al. The effect of weight loss on lameness in obese dogs with osteoarthritis. Vet Res Commun 2010; 34: 241–253.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 59. Wucherer KL, Conzemius MG, Evans R, et al. Short-term and long-term outcomes for overweight dogs with cranial cruciate ligament rupture treated surgically or nonsurgically. J Am Vet Med Assoc 2013; 242: 1364–1372.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 60. Toda Y, Toda T, Takemura S, et al. Change in body fat, but not body weight or metabolic correlates of obesity, is related to symptomatic relief of obese patients with knee osteoarthritis after a weight control program. J Rheumatol 1998; 25: 2181–2186.

    • Search Google Scholar
    • Export Citation
  • 61. Hielm-Björkman AK, Kapatkin AS, Rita HJ. Reliability and validity of a visual analogue scale used by owners to measure chronic pain attributable to osteoarthritis in their dogs. Am J Vet Res 2011; 72: 601–607.

    • Crossref
    • Search Google Scholar
    • Export Citation

Advertisement